There is an unmet need for targeted therapy for human epidermal growth factor receptor 2–negative (HER2-negative), locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma (advanced G/GEJa), which is associated with poor survival outcomes. Here, ERBB2 is linked to gastroesophageal junction adenocarcinoma.